Millions of people suffer from movement disorders. Praxis Precision Medicines wants to help meet the large unmet need for effective treatment options. Praxis specializes in using genetic insights to ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Praxis Precision Medicines (PRAX) is back in focus after multiple analysts, ...

As artificial intelligence rushes onto our campuses, tutoring has become a telling test case for how easily we might trade human connection for apparent technological convenience. The appeal is ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy pipeline. Ulixacaltamide’s Essential3 data appear statistically robust, but a ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor. Praxis on ...

You’ve heard of laid-off workers training their lower-paid replacements. Now imagine that the replacement worker is a robot. Something like that is going on in Watertown, at a company called Tutor ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny. According to the short report, Praxis engineered its October 2025 results ...

The prescription was everywhere as the full extent of academic damage wrought by the pandemic first became clear: Set up tutoring programs to catch students up. Now, though, several evaluations of ...

LONDON, ENGLAND - OCTOBER 09: A general view of the Google DeepMind offices after the announcement that Founder and CEO Demis Hassabis and senior research scientist, John M. Jumper, received the 2024 ...

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...